Special Issue "Molecular Pathology of Glioma"
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 160
Special Issue Editor
Interests: brain tumors; next generation sequencing; copy number variation; immunohistochemical biomarkers; glioblastoma; glioma
Special Issue Information
This Special Issue is dedicated to the molecular pathology of gliomas. Following the 5th edition of the WHO Classification of Central Nervous System Tumours (2021), gliomas encompass adult-type diffuse gliomas, paediatric-type diffuse low-grade gliomas, paediatric-type diffuse high-grade gliomas, and circumscribed astrocytic gliomas. In order to render an integrated diagnosis, molecular analyses are of the utmost importance. The rationale of various laboratories for choosing a specific panel of molecular tests represents an important aspect in order to address questions raised in the process of accreditation of diagnostic laboratories.
Since the pathogenetic mechanisms at work in this tumour group remain enigmatic in many aspects, we welcome papers that address the molecular biology of gliomas and new techniques to study tumour tissue and translational studies, bringing a molecular understanding into clinical context and applied settings. Papers featuring a correlation between pathology, molecular data and survival are of interest.
Dear Colleagues,
We are pleased to invite you contribute to the Special Issue “Molecular Pathology of Gliomas”. The subject relates perfectly to the journal’s scope, which is centred on the many diverse aspects of cancers affecting various human organs.
This Special Issue aims to address a multitude of molecular aspects at the level of pathogenicity, diagnostics, and translation into the clinical realm.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: next generation sequencing, epigenetics, miRNA, transcriptomics, lipidomics, radiogenomics, Raman spectroscopy.
We look forward to receiving your contributions.
Prof. Dr. Serge Weis
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- genomics
- NGS
- miRNA
- proteomics
- transcriptome
- metabolomics
- lipidomics
- epigenetics
- Raman spectroscopy
- radiogenomics
